Skip to main content
Figure 6 | Cancer Cell International

Figure 6

From: Targeting different types of human meningioma and glioma cells using a novel adenoviral vector expressing GFP-TRAIL fusion protein from hTERT promoter

Figure 6

In vivo antitumor activity of Ad/gTRAIL: (A) Survival of animals treated with Ad/gTRAIL. Nude mice bearing intracranial M6 and U-87 xenografts were injected intratumorally with Ad/CMV-GFP or Ad/gTRAIL at doses of 1.5 × 108 viral particles in 5 μL for 3 days. The Kaplan-Meier survival curve for each group was shown in the paragraph (n = 6 animals in each group). The mean survival for the control mice Ad/CMV-GFP) was 19 days in M6 and 26 days in U87 respectively. In contrast, the survival for the Ad/gTRAIL treated mice was 61 days in M6 and 63 days in U87, which was statistically significantly longer than the mean survival of control mice (p< 0.05). (B) The athymic mice brain section (B1) with Meninglioma xenograft (B2).

Back to article page